SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology

Kamm, Christian P; Mattle, Heinrich P (2009). SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology. Trials, 10, p. 115. London: BioMed Central 10.1186/1745-6215-10-115

[img]
Preview
Text
1745-6215-10-115.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (337kB) | Preview

Statins have anti-inflammatory and immunomodulatory properties in addition to their lipid-lowering effects. Currently, the effects of statins on multiple sclerosis are still controversial. Therefore, randomized clinical trials are needed to provide better evidence on the therapeutic potential of statins in multiple sclerosis. The SWiss Atorvastatin and Interferon Beta-1b trial in Multiple Sclerosis (SWABIMS) evaluates the efficacy, safety and tolerability of atorvastatin 40 mg per os daily and subcutaneous interferon beta-1b every other day compared to monotherapy with subcutaneous interferon beta-1b every other day in patients with relapsing-remitting multiple sclerosis.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Kamm, Christian Philipp and Mattle, Heinrich

ISSN:

1745-6215

Publisher:

BioMed Central

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:14

Last Modified:

17 Jan 2019 17:26

Publisher DOI:

10.1186/1745-6215-10-115

PubMed ID:

20003436

Web of Science ID:

000273286900001

BORIS DOI:

10.7892/boris.32430

URI:

https://boris.unibe.ch/id/eprint/32430 (FactScience: 197611)

Actions (login required)

Edit item Edit item
Provide Feedback